An investigation of the differential therapeutic effects of romosozumab on postmenopausal osteoporosis patients with or without rheumatoid arthritis complications: a case–control study
Authors' conclusion
The efficacy of ROMO may be attenuated by RA-related factors.
Study context
- Population
- Postmenopausal osteoporosis patients not receiving oral GC, treated with romosozumab (mean age 76.3 years)41 per group after propensity matching
- Participants
- 59 vs 121
- Exposure
- Romosozumab (ROMO) in postmenopausal osteoporosis with rheumatoid arthritis (RA) vs without RA
- RAn = 59
- non-RAn = 121reference
- Outcome
- BMD change (LS, total hip)
- Follow-up
- 12 months
Methodological detailsmulticenter, propensity score matching
- Multicenter
- Propensity score matching
Main finding
As reported in the abstract
BMD increase, LS
P = 0.013
Observational data: associations, not effects.
Further findings
BMD increase, total hip · 12 months · propensity score matched
P = 0.025
Bone turnover markers (PINP increase, TRACP-5b decrease)
- Trend toward smaller changes in the RA group vs non-RA, implying a smaller anabolic window
RA-specific factors and 12-month bone mineral density (BMD) change (all RA, n = 59)
- Negative correlation between ACPA titer and lumbar spine (LS) BMD and between health assessment questionnaire disability index (HAQ-DI) and femoral neck BMD
- Multiple regression analysis
Original publication
An investigation of the differential therapeutic effects of romosozumab on postmenopausal osteoporosis patients with or without rheumatoid arthritis complications: a case–control study. Osteoporos Int. Published 31 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →